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Introduction
MicroRNA signature of THP1 cells revealed a 5.9-fold
decreased expression of miR-4520a following siRNA-
mediated knockdown of MEFV gene that encodes
pyrin [1].
Objectives
We herein sought to validate the expression levels of
miR-4520a in monocytes isolated from peripheral blood
mononuclear cells (PBMCs) of FMF patients.
Methods
Dual luciferase assay was used to validate a predicted
miR-4520a recognition element in the 3’UTR region of
the Rheb gene. The expression levels of pyrin, miR-
4520a and its putative target Rheb were validated in
monocytes from FMF patients (n=9) and compared with
healthy controls (n=8). Patients were off colchicine for
two days (attack-free period) and monocytes were iso-
lated from PBMCs. Total RNA together with the respec-
tive miRNA-enriched fractions were isolated from
monocytes and used for mRNA and miR-4520a quanti-
tation by real-time PCR using the 2-ΔΔCt method after
normalizing to 18S RNA and RNU6B genes, respec-
tively. Protein levels of pyrin and Rheb were detected by
western blotting.
Results
The relative expression levels of miR-4520a were vari-
able among FMF patients and not significantly different
between patients and controls. However, when patients
that did not harbor any mutations in MEFV were
excluded from the analyses, the expression of miR-
4520a was statistically different between FMF patients
and controls (p<0.05), indicating an association between
miR-4520a expression and mutations in the MEFV gene.
Moreover, stratification of patients group by genotype
revealed an intriguing difference in miR-4520a relative
expression, with carriers of M694V variant (combined
group of homozygotes, heterozygotes and compound
heterozygotes) showing the highest increase (p<0.05).
Subsequent comparison between the M694V group and
healthy controls showed a significant increase in miR-
4520a expression levels that remained significant even
after bonferroni correction (p<0.01). Interestingly, one
of the homozygote M694V patients with the highest
fold change in miR-4520a expression (FC=7.8) experi-
enced an FMF-attack while on study, with a concomi-
tant decrease in miR-4520a relative expression
(FC=0.45). Bio-informatic analyses showed that miR-
4520a is predicted to target genes implicated in autop-
hagy through regulation of Rheb/mTOR signaling.
Expression levels of Rheb were confirmed by luciferase
reporter gene assays providing further evidence that
Rheb is a direct target of miR-4520a (p<0.01). Validation
of pyrin and Rheb protein expression levels in mono-
cytes from FMF patients is in progress.
Conclusion
Our findings provide initial evidence that Rheb is a valid
target of miR-4520a and suggest that a dysfunctional
pyrin due to gain of function mutations with a dosage
effect [2], especially of M694V variant, may be asso-
ciated with an increase in miR-4520a expression levels,
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thus contributing to deregulated mTOR signaling and
subsequently IL-1b release [3].
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